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Abstract. Liver impairment can be caused by a significant number of foreign compounds (xenobiotics); prescribed 
drugs, ‘over the counter’ (OTC) drugs, herbal and alternative medicines. Hepatotoxicity caused by drugs used for 
therapeutic, recreational or nutritional purposes as well as drugs of abuse is a drug-induced liver disease (DILD). Over 
300 agents in use have been connected with causing DILD. Factors associated with increased susceptibility to DILD are: 
age, gender, genetic predisposition, dose, other drug reactions, concomitant use of drugs, excessive use of alcohol, 
nutritional status, liver disease and other diseases. Drugs may cause liver injury in a predictable, dose-dependant 
manner (intrinsic DILD), or in an unpredictable, non-dose-dependant manner (idiosyncratic DILD). Xenobiotics that 
cause liver impairment provide a wide range of lesions resembling many other liver diseases. Acute hepatocellular 
damage can be cytotoxic (hepatocellular necrosis), cholestatic (associated with the interrupted flow of bile), or mixed. 
Clinical expressions of DILD range from nonspecific abnormalities of liver tests, to cholestasis, acute hepatitis and acute 
liver failure. Nodular hyperplasias, chronic hepatitis, autoimmune hepatitis, fibrosis, NASH, cirrhosis, benign and 
malignant liver tumours have been reported. Diagnosis of DILD is based on history, blood tests, imaging examination of 
hepatobiliary tract and, if applicable, liver biopsy. Clinical and laboratory findings in DILDs are not always in line with 
liver pathology. Histologic changes can be minor compared to biochemical findings. Liver enzymes are not synonym of 
liver damage. 




Significant increase of scientific studies investigating 
drug-induced liver disease (DILD) in the last few years is 
making DILD an emerging safety issue that requires 
attention by medical professionals in clinical practice, 
regulatory authorities, pharmaceutical companies and 
academic institutions [1]. Liver impairment can be caused 
by a significant number of foreign compounds 
(xenobiotics); prescribed drugs, „over the counter‟ (OTC) 
drugs, herbal and alternative medicines. Chemical agents 
widely used in households, drugs of abuse, pesticides, 
herbicides may have toxic and/or carcinogenic properties. 
Hepatotoxicity caused by drugs used for therapeutic, 
recreational or nutritional purposes as well as drugs of 
abuse is a drug-induced liver disease (DILD). About 14-
19 per 100 000 inhabitants in general population is the 
reported frequency of DILD. Health care system records 
the incidence of about 30-32 per 100 000 persons [2,3]. 
According to available data, 462 medicinal products were 
withdrawn from the market between 1953 and 2013. 
Hepatotoxicity was the most reported adverse drug 
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reaction causing post marketing drug withdrawal (81 
cases; 18%). Withdrawals were significantly less 
common in Africa than in Asia, Europe, and America [4].  
In the largest number of reports, DILD is unpredictable 
because of its idiosyncratic nature. Accurate underlying 
mechanisms (mitochondrial injury, reactive metabolites, 
biliary transport inhibition, and immune responses) have 
been identified rarely. DILD can occur in case of 
accidental or intentional overdose or during the use of a 
drug for therapeutic purposes in certain clinical 
circumstances, as in the case of paracetamol in patients 
who regularly consume alcohol [5]. Paracetamol is the 
leading cause of acute liver failure, whereas 
chlorpromazine, halothane, sulpiride and amoxicillin-
clavulanate were found as most common drugs leading to 
hepatotoxicity in all prospective studies [6]. The list of top 
10 drugs implicated in DILD consists of antibiotics, statins, 
antitumor necrosis factor antagonists (infliximab as 
leading); herbal and dietary supplements (most frequent 
causes of serious hepatotoxicity are weight loss and 
bodybuilding products) [7]. 
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Risk Factors for Incidence  
and Severity of DILD 
Factors associated with increased susceptibility to DILD 
are: age, gender, genetic predisposition, dose, other drug 
reactions, concomitant use of drugs, excessive use of 
alcohol, nutritional status, liver disease and other 
diseases. Age more than 60 increases the frequency and 
severity of DILD caused by isoniazid and halothane. 
Children are more commonly affected by salicylates. 
Women are at an increased risk of developing 
hepatotoxicity from halothane, nitrofurantoin and men 
from amoxicillin-clavulanate and azathioprine. 
Concomitant use of acetaminophen and isoniazid, 
zidovudine and phenytoin lower the hepatotoxic dose and 
increase severity of DILD. Obesity increases the risk of 
liver injury by halothane, methotrexate and tamoxifen, 
while malnutrition increases the risk of liver injury by 
acetaminophen. Genetic variation at human leukocyte 
antigen (HLA) class I & II loci has been shown to be 
associated with amoxicillin–clavulanate DILD. The 
strongest association thus far identified is at a single 
nucleotide polymorphism in the gene encoding the class 
II HLA-DRB1* 1501-DQB1* 0602 allele [8,9]. 
Variations of genes for mitochondrial DNA polymerase 
gamma are associated with valproate hepatotoxicity [10].  
Mechanisms of Drug Injury 
Drugs may cause liver injury in a predictable, dose-
dependant manner (intrinsic DILD), or in an unpredictable, 
non-dose-dependant manner (idiosyncratic DILD).  
In most cases of the drug induced liver injury, the 
same happens in an unpredictable manner and only in 
susceptible individuals (idiosyncrasy or hypersensitivity). 
Impairment may appear from toxic metabolites which 
affect cell proteins. Toxic metabolites cause necrosis 
(metabolic idiosyncrasy) or form antigen (drug hapten) 
complexes which stimulate T cells, inducing an immune 
reaction and causing hepatic impairment (hypersensitivity 
or drug allergy). Drug-induced hypersensitivity reactions 
are commonly merged with systemic reactions, such as 
fever, rash and eosinophilia. They have a fixed latent 
period and prompt response to a repeated provocation. 
This reflects an underlying immunological mechanism. 
Vice versa, atypical metabolism of a drug which leads to 
formation of toxic metabolites, generally does not cause 
systemic allergic manifestations and it has a long or 
variable latency period and frequently a late response to a 
repeated provocation [11,12,13]. The most common 
causes of idiosyncratic damage are amoxicillin-
clavulanate, nitrofurantoin, co-trimoxazole, ciprofloxacin, 
isoniazid, tyrosine kinase inhibitors [14]. 
A very small number of currently used medicinal 
products cause liver injury as a result of intrinsic toxicity 
or toxicity of one or more of their metabolites 
(predictable or intrinsic hepatotoxicity) [15]. Paracetamol 
is hepatotoxic due to production of the toxic metabolite as 
a result of accidental or intentional overdose or when 
used in recommended doses in circumstances of chronic 
use or alcohol abuse or starvation. The actual cause of 
damage to hepatocytes or cell death is damage or 
destruction of cell membranes or covalent binding of 
toxic metabolites to liver macromolecules causing a 
disturbance in calcium homeostasis, mitochondrial 
dysfunction or decay of other cell systems.  
Acetaminophen (paracetamol) accounts for 50% of all 
drug-induced acute liver damage. Its metabolite, N-
acetyl-p-benzoquinone imine (NAPQI), is created in 
hepatocytes. This toxic metabolite is reduced by 
glutathione. Reduced capacity of glutathione leads to 
impairment of vital processes in the cells and to their 
death. Paracetamol induced liver disease is treated with n-
acetyl cysteine, in the first 8 hours of introduction of the 
drug [16].  
Nimesulide, diclofenac, ibuprofen are non-steroidal 
anti-inflammatory drugs (NSAIDs) widely used in 
therapy of most rheumatological disorders, as analgesics 
and antipyretics, as prescription drugs and over the 
counter drugs. Nearly all NSAIDs are associated with 
hepatotoxicity; several NSAIDs have been withdrawn 
from the market (amphenac, ibufenac, phenylbutazone, 
fluproquazone). The new more selective COX-2 
inhibitors (e.g. celecoxib, rofecoxib, nimesulide) are also 
connected with hepatotoxicity. Pathogenic mechanisms 
include oxidative stress alone or in combination with 
mitochondrial injury [17]. 
Oral contraceptive steroids and 17-alkylated anabolic 
steroids are associated with cholestasis, vascular lesions 
and hepatic neoplasms.  
Drugs of abuse like cocaine or 3,4 
methyenediomatamphetamine (“ecstasy”) are related to 
hepatotoxicity. Cocaine toxicity is related to P450 
catalysed N-demethylation to norcocaine, converted to N-
hydroxynorcocaine. The latter redoxcycles to norcocaine 
nitroxide by receipt of an electron from NADPH, and 
transfers electrons to O2, generating oxidative stress [17]. 
The frequency of hepatic injury with antiretroviral 
drugs is at least 10%. Hepatic failure has been reported in 
patients taking zidovudine, but didanosine and stavudine 
have been most often involved in severe hepatotoxicity 
due to mitochondrial damage. Nevaripine has been 
implicated in causing severe hepatotoxicity. Ritonavir, 
Indinavir, Saquinavir, Nelfinavir have been reported for 
hepatotoxicity. Anti-retrovirals can induce direct toxicity 
in the liver, mitochondrial toxicity; hypersensitivity 
reactions have been reported relatively often with 
nevirapine and abacavir. Newer anti-HIV drugs like 
raltegravir, maraviroc and enfuvirtide have not been 
associated with significant hepatotoxicity [18]. 
The frequency of the DILD with recently introduced 
drugs will be known after larger studies. Nature of liver 
injury is presented in Table 1 [18]. 
Xenobiotics that cause liver impairment provide a wide 
range of lesions resembling many other liver diseases. 
Acute hepatocellular damage can be cytotoxic 
(hepatocellular necrosis), cholestatic (associated with the 
interrupted flow of bile), or mixed. In addition to 
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hepatocellular necrosis or cholestasis, other types of liver 
lesions could be induced by xenobiotics. Fatty change of 
the liver (steatosis) is common. Macrovesicular steatosis 
refers to large drops of fat and the core is replaced by a 
large intracytoplasmic lipid globule. Microvesicular 
steatosis is characterized by small drops of fat within the 
cytoplasm that do not suppress the core. Some drugs are 
associated with the formation of Mallory's bodies. Hepatic 
granulomas are a typical damage caused by certain drugs. 
Various forms of chronic liver impairment resembling 
chronic active hepatitis, chronic cholestasis and cirrhosis 
can be caused by xenobiotics.  
Vascular disorders of the liver caused by medicinal 
products include a venous-occlusive disease, very similar 
to Budd-Chiari‟s syndrome. Peliosis hepatis is formation of 
blood cysts within the liver. Several drugs disrupt lipid 
metabolism in the hepatocytes by inhibiting phospholipase, 
which gives a foamy texture cytoplasm and characteristic 
ultrastructural liposomal appearance (phospholipidosis). 
Finally, certain drugs and chemicals are associated with 
hepatic neoplasia. Benign hepatic adenomas appear after 
the introduction of oral contraceptive steroids.  
Clinical Expressions of DILD 
Clinical expressions of DILD range from nonspecific 
abnormalities of liver tests, to cholestasis, acute 
hepatitis and acute liver failure. The most common form 
of presentation of DILD is an acute viral “hepatitis-like” 
syndrome, with jaundice, nausea, fatigue and abdominal 
discomfort or pain. DILI can virtually mimic any other 
liver disease such as chronic hepatitis, autoimmune 
hepatitis, fibrosis, NASH, cirrhosis, benign and even 
malignant liver tumours [19]. 
Clinicopathological classification of DILD is presented 
in Table 2. 
Biochemical Classification  
Biochemical classification of liver damage caused by drugs 
include hepatocellular, cholestatic and mixed pattern. R 
value is calculated to assist in diagnosis and management 
of DILD. In case there is evidence of drug or supplement 
use in previous 6 months, and elevated liver enzymes are 
detected, R value is calculated as follows:  
R = (ALT value / ALT ULN) / (ALP value / ALP ULN) 
If R   2 cholestatic damage is susceptible. Ultrasound 
of abdomen should be done and MRI/MRCP are to be 
considered. If R is between 2 and 5 mixed pattern and R   
5 hepatocelular liver damage is suggested. In these cases 
testing for hepatitis A, B, C and E should be done, as well 
as ultrasound imaging. In consideration are testing for 
EBV, HSV, autoimmune hepatitis etc.  
Table 1 Histologic pattern and clinical expressions of DILD  
Drug Liver injury 
Alfuzosin Hepatocellular od mixed hepatocellular-cholestatic injury 
Beta interferon Liver injury rare, autoimmune hepatitis 
Bosentan, sitaxsentan Acute hepatitis 
Imatinib mesilate and other tyrosine kinase 
inhibitors 
Acute hepatitis, massive or submissive hepatic 
necrosis(rare); acute liver failure with sunitinib 
Leukotriene antagonists (zafurlukast, montelukast) Massive or submissive hepatic necrosis (zafirlukast), 
acute hepatitis, cholestitis hepatitis (montelukast) 
Infliximab and other tumor necrosis factor antagonists Cholestasis, cholestatic hepatitis, hepatic granuloma, 
autoimmune hepatitis 
Ximelagatran Acute liver failure (not finally proven) 
Table 2 Clinicopathological classification of DILD 
Damage type Drug 
 Acute hepatocellular injur  Isoniazid, aspirin, sulphonamide 
 Autoimmune hepatitis Nitrofurantoin, minocycline, ipilimumab 
 Pure cholestasis Anabolic steroid, oestrogens 
 Macrovesicular steatosis Tetracycline, steroids, gold, 5-fluorouracil, methotrexate, tamoxifen 
 Microvesicular steatosis Tetracycline, steroids, gold, 5-fluorouracil, methotrexate, tamoxifen,  
 Cholestasis hepatitis  Phenytoin, AC, fluoroquinolones, macrolides, azithromycin 
 Granulomatous hepatitis Isoniazid, interferon, phenytoin, allopurinol 
 Chronic hepatitis Phenytoin, AC, fluoroquinolones, macrolides, azithromycin 
 Non-Alcohol fatty liver Tamoxifen, Amiodarone 
 Fibrosis/cirrhosis Metotrexate, amiodarone 
 Liver Adenoma Oral contraceptives 
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Diagnosis of DILD 
Diagnosis of DILD is based on history, blood tests, 
imaging examination of hepatobiliary tract and, if 
applicable, liver biopsy. There are no specific laboratory 
tests, histological presentations, or clinical signs and 
symptoms enabling the diagnosis of DILD. Signs and 
symptoms vary with the drug, host, and severity of 
injury [20]. 
Some situations where the probability of the existence 
of DILD is likely are summarized in Table 3 [18]. 
The diagnostic evaluation of DILD usually includes 
evaluation of data summarized in Table 4 
Liver biopsy is indicated in cases in which liver 
disease remains in doubt and this uncomfortable and 
risky procedure will make a difference in management 
of the injury. Liver biopsy is reasonable in case when 
continued use or re-challenge with a suspected drug is 
clinically necessary. For patients receiving methotrexate 
there are guidelines for biopsy [21,22]. Other situations 
where liver biopsy could be recommended are: 
exacerbation of liver function in spite of stopping drug 
exposure, unexpected decreases of ALT within 30-60 
days in hepatocellular or ALP within 180 days in 
cholestatic DILDs despite termination of use of the 
suspected drug [13].  
 
Fig 1 Calculation of R value and use in DILD management [15] 
 
Table 4 The diagnostic evaluation  
 history (use of drugs, herbal or dietary supplements; 
possibility of drug interaction; exposure time/latency, 
alcohol intake, chronic liver disease, concomitant 
diseases (diabetes, heart failure))  
 signs and symptoms (weakness, fatigue, fever, yellow 
urine, nausea, vomiting, abdominal pain, abdominal 
bleeding, rash, pruritus, icterus, ascites) 
 initial laboratory tests (compete blood count 
(eosinophilia), liver function testing (AST, ALT, GGT, 
R value) 
 routine serological tests (Acute viral hepatitis A, B, C 
(Anti –HAV IgM, HbsAg, anti-HBc IgM, anti – HCV, 
HCV RNA, autoimmune hepatitis ( ANA, IgG level)) 
 serological tests by patients history (hepatitis E (anti 
hepatitis E virus IgM), CMV, EBV, HSV) 
 other investigations (for Wilson‟s disease, etc.)  
 imaging studies (Ultrasound, CT, MRCT) 
ALP (alkaline phosphatase); ALT (alanine 
aminotransferase); ANA (antinuclear antibody); CMV 
(cytomegalovirus), CT (computed tomography), EBV 
(Epstein Bar virus); GGT (gamma –glutamyl transferase, 
HAV (Hepatitis A virus); HBc (Hepatitis B core antigen); 
HBsAg (Hepatitis B surface antigen); HCV (Hepatitis C 
virus) ; HSV (hepatitis C virus); HSV (herpes simplex 
virus); IgG (immunoglobin G); IgM (immunoglobin M); 
MRCP (magnetic resonance imaging, RNA (ribonucleic 
acid); ULN (upper limit of normal range). 
Table 3 Situations in which the existence of DILD is likely  
 Introduction of a new therapy in the last 3-6 months; 
 Evidence of extrahepatic manifestations like rash, 
eosinophilia, lymphadenopathy; 
 Acute hepatitis not connected to hepatitis viruses, 
other infections, metabolic, immunologic disorders; 
 Mixed hepatocellular and cholestatic injury; 
 Hepatitis with microvesicular steatosis; 
 Cholestasis with normal bile duct imaging; 
 Chronic hepatitis without antibodies; 
 Liver disease after years of taking steroids, 
immunosuppressive or other drugs, etc. 
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The Council for International Organizations of Medical 
Sciences has created a CIOMS/RUCAM questionnaire. 
Score count is based on timing of exposure and liver 
biochemistry washout, competing medications and 
diagnoses, re-challenge of data and risk factors for DILI. 
Additional methods have been developed. One of them is 
Naranjo Adverse Drug Reaction Probability Scale 
(NADRPS). The CIOMS/RUCAM is widely used and 
considered the best assessment method respecting 
sensitivity and predictive value. Likelihood levels are: 
„highly probable‟ (> 8), „probable‟ (6 – 8), „possible‟ (3 – 
5), „unlikely‟ (1 – 2), and „excluded‟ (score < = 0). 
RUCAM score system is separated into hepatocellular 
injuries; cholestatic or mixed injuries form [23].  
Prevention 
Liver function testing is recommended before starting the 
treatment along with safety monitoring during therapy with 
agents with known hepatotoxicity and in case treatment 
extends for longer than 2-4 weeks. However, with respect 
to the costs of such screening, it is difficult to define the 
threshold at which the drug should be discontinued 
especially in case of absence of symptoms. 
Generally, it is recommended that the drug should be 
stopped if ALT level exceeds five times ULN. Abnormal 
bilirubin level, albumin concentration, prothrombin time 
and symptoms are clear indications to stop the therapy. 
The monitoring of the liver tests is strongly 
recommended in case of treatment with the following 
agents: methotrexate, isoniazid, retinoids, ketoconazole, 
anticancer drugs, and minocycline in prolonged time 
[18,24]. 
Treatment of DILD 
There are varied presentations and multiple possible drug 
causes. The treatment of all cases is withdrawal of the 
suspecting agent. If a DILD is caused by acetaminophen or 
in case of Amanita mushrooms intoxication, appropriate 
therapy should be administered. All patients can now be 
considered for NAC therapy, especially adults with early-
stage of ALF (acute liver failure). Patients should be 
monitored for normalization of biochemical tests. In cases 
when it is recognized as lifesaving, Early liver 
transplantation is recommended in cases where it is 
recognized as a lifesaving procedure [25]. 
Prognosis 
The prognosis is highly variable depending on the clinical 
presentation and degree of liver damage. In general, 
outcomes of idiosyncratic DILI are good, with about 10% 
reaching the ALF (coagulopathy and encephalopathy). 
The outcome of acute liver failure is determined by 
aetiology, the degree of hepatic encephalopathy, and 
complications such as infections. DILI developing to 
ALF carries a poor prognosis. Mortality rate of DILD is 9 
to 12%. Only 20% to 25% of patients with acute 
idiosyncratic fulminant hepatic failure survive 3 weeks 
without liver transplantation. The causes of death include 
cerebral oedema, sepsis, multiple organs insufficiency, 
cardiac and respiratory failure [13,15]. In cases with 
existing liver disease, increased morbidity and mortality 
have been reported. Prognosis is worse the longer a 
patient is exposed to hepatotoxin.  
Mixed type of liver damage often progresses into a 
chronic form with cirrhosis. Immune type of damage 
(eosinophils and granulomas on biopsy) has a better 
prognosis. Pure hepatocellular necrosis in biopsy has a 
worse prognosis [14]. 
Categorisation of the Probability of DILD  
According to the Drug-Induced Liver Injury Network 
(DILIN) assessment causality of probability to induce 
liver injury, drugs are classified in five categories of 
probability to induce DILD. This assessment is based on 
published data and is more precise for widely prolonged 
use of medicines than nearly approved drugs or herbal 
products [26]. 
Table 5 Categorisation of the probability of DILD 
Category A. Medicines from this category are well known, 
well described, well reported to cause either direct or 
idiosyncratic liver injury. The number of described cases 
is more than 50 
Category B. Known or highly likely drugs reported to 
cause idiosyncratic liver injury. The number of described 
cases is between 12 and 50 cases including small case 
series. 
Category C. Probably linked drugs to induce idiosyncratic 
liver injury, reported uncommonly. The number of 
identified cases is less than 12 without significant case 
series. 
Category D. Possible hepatotoxic drugs that rarely cause 
liver injury. The number of identified cases is less than 3. 
Category E. Drugs with no evidence that has caused liver 
injury. Mostly inconclusive single case reports have been 
published. 
Category E*. Agents with reported DILD in extensive 
clinical studies, but with insufficient supportive causality 
data. Hepatotoxicity is unproven, but suspected.  
Category X. Medicines quite recently presented or seldom 
used in clinical practice with luck of data on risk for 
developing of DILD (“unknown” category). 
A [HD], B [HD], C [HD] or D [HD] category. Medicines 
that induce liver damage in cases of overdose. Most 
common used agents from this category are aspirin, 
acetaminophen, naicin and vitamin A. 
Liver disease associated with particular drugs 
Amoxicillin-clavulanate 
The incidence of DILD is 1.7 per 10,000 prescriptions. It 
is more common in the elderly with a concomitant 
therapy. It occurs more frequently in individuals who are 
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heterozygous for a mutant form of the gene for glutathione-
S-transferase. The injury starts within 6 weeks of therapy 
with amoxicillin-clavulanate. Cholestatic type of damage is 
common and other forms are possible, as well. 
Recovery period is 3-6 months. About 3% of injured 
finished with acute renal insufficiency or progression to 
cirrhosis [13). 
Fluoroquinolones 
The latency period is short (from 2 to 9 days). Common 
type of injury is immune damage. Prognosis is better than 
in case of DILD induced by amoxicillin-clavulanate. It is 
more common in people who are allergic to 
fluoroquinolones. Liver damage is a „class effect‟ of 
fluoroquinolones [15]. 
Tyrosine kinase inhibitors 
Liver damage occurs in the first 8 weeks after initiation of 
therapy. It can be manifested as a mild form - only an 
increase in transaminases, which passes spontaneously 
after discontinuation of medication. The severe form is 
presented as hepatocellular injury, and the incidence is 2-
3% of total number of treated patients [13].  
Direct-acting oral anticoagulants (DOACs) 
Liver damage during administration of therapeutic doses of 
direct-acting oral anticoagulants has been reported in the 
past few years. Post marketed data reported rivaroxaban as 
the agent with the highest risk in the group. A 
pharmacological and chemical characteristic of direct-
acting anticoagulants seems to be associated with drug-
induced liver injury risk. Rivaroxaban, dabigatran and 
apixaban contain structural elements connected to 
metabolism and/or reactive metabolites connected to DILD 
occurrence in humans. Host factors seem to have influence 
on DILD occurrence. DILD induced by DOACs therapy of 
venous thromboembolism in surgical patients is reported 
more frequently then atrial fibrilation [27]. 
Herbal and Dietary supplement-induced liver injury 
The increasing use of alternative medicines has led to 
many reports of toxicity. The spectrum of liver disease is 
wide. Herbal and Dietary supplements do not pass 
preclinical and clinical toxicology safety testing or clinical 
trials for safety. A dietary supplement consists of vitamins, 
minerals, amino acids, enzymes, tissues extracts, 
metabolites, etc. Herbal and Dietary Supplements (HDS) 
are widely consumed and in most cases without medical 
observation. Some of these products have been reported to 
induce liver injury. First of all, body-building products, 
which contain anabolic steroids are associated with an 
initial cholestatic hepatitis followed by prolonged jaundice 
[28]. Pyrrolizidine alkaloids can induce sinusoidal 
obstruction syndrome [29]. In some cases, flavocoxid, has 
been associated with severe liver injury [30]. The same 
diagnostic approach for DILI is applicable to suspected 
HDS hepatotoxicity. Patients should stop using HDS 
products and be monitored until hepatotoxicity has been 
resolved. 
Individual susceptibility is important for herbal-
induced drug injury. Kava, anxiolytic agent is connected 
to hepatotoxicity in Caucasians with low expression of 
CYP2D6. Some herbs initiate immunoallergic liver injury 
(jin bu huan). Rarely, herbal medicines may trigger latent 
liver disease (dai-saiko–to, black cohosh). Herbal 
hepatotoxicity could be presented as acute hepatitis, 
steatosis, fibrosis to submassive and massive hepatic 
necrosis (chaparral leaf). Some herbal agents and dietary 
supplements implicated as causing toxic liver injury are 
presented in Table 6 [13]. 
Discussion/Conclusion 
Clinical and laboratory findings in DILDs are not always 
in line with liver pathology. There are significant 
differences between categories. Histologic changes can be 
minor compared to biochemical findings. Liver enzymes 
are not synonym of liver damage. Some drugs, like 
estrogens, are associated with high levels of AT and mild 
cholestasis on biopsy can be recorded. 
Drugs like methotrexate, arsenic can cause cirrhosis 
with minimal changes in laboratory tests. Model of liver 
tests is nonspecific and often mixed. Various forms of 
injury can be seen: steatohepatitis, cholestatic hepatitis, 
chronic hepatitis, minor nonspecific liver injury. 
Most cases of drug-induced dysfunction are 
reversible. In general, discontinuation of hepatotoxin 
results in rapid reversal of signs and symptoms if the 
Table 6 Herbal agents and dietary supplements implicated as causing toxic liver injury 
Herbal remedy Indication Pattern of liver injury 
Atractylis gummifera Purgative, diuretic Acute liver failure 
Black cohosh Menopausal symptoms Acute liver failure, could trigger autoimmune hepatitis 
Chinese herbal medicines Multiple use Liver injury, Acute hepatitis 
Germander tea and capsules  Weight reduction, health tonic Acute and chronic hepatitis, acute liver failure, hepatic 
fibrosis 
“Green juice” Dietary supplement Granulomatous hepatitis 
Herbalife® Health supplement Acute hepatitis, Cholestasis 
Kava Anxiety disorder Diffuse hepatocellular necrosis, Cholestatic hepatitis 
Kombucha Health tonic Acute hepatitis 
LipoKinetix® Slimming aid Acute hepatitis, acute liver failure 
Shark cartilage Food supplement Abnormal liver tests 
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injury is mild to moderate. A 50% reduction of hepatic-
associated enzymes can be expected within 1 week if the 
injury is hepatocellular, but this degree of improvement 
may take 6 months or longer if the injury is cholestatic. 
In most cases, management of drug-induced liver 
dysfunction is limited to supportive care, as therapeutic 
treatment is applicable in only a small number of 
situations. 
Liver function testing before starting of the treatment 
and safety monitoring during the therapy with agents with 
known hepatotoxicity and in case treatment will extend 
for longer than 2-4 week is recommended. Monitoring of 
the liver tests is strongly recommended in case of 
treatment with the following agents: methotrexate, 
isoniazid, retinoids, ketoconazole, anticancer drugs, and 
minocycline in prolonged time. Herbal and Dietary 
Supplements (HDS) are widely consumed and in most 
cases without medical observation. Some of these 
products have been reported to induce liver injury. 
Patients should stop using HDS products and they should 
be monitored until hepatotoxicity has been resolved. 
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